Your browser is no longer supported. Please, upgrade your browser.
Settings
NOVN Novan, Inc. daily Stock Chart
NOVN [NASD]
Novan, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own1.90% Shs Outstand27.00M Perf Week-6.34%
Market Cap71.82M Forward P/E- EPS next Y-0.84 Insider Trans10.80% Shs Float16.85M Perf Month-6.01%
Income-28.40M PEG- EPS next Q-0.31 Inst Own11.80% Short Float0.94% Perf Quarter-9.52%
Sales2.70M P/S26.60 EPS this Y76.70% Inst Trans-5.07% Short Ratio4.40 Perf Half Y-9.52%
Book/sh0.17 P/B15.65 EPS next Y25.00% ROA-84.10% Target Price10.00 Perf Year-48.94%
Cash/sh0.78 P/C3.42 EPS next 5Y- ROE-591.80% 52W Range2.27 - 6.69 Perf YTD-36.97%
Dividend- P/FCF- EPS past 5Y- ROI-574.40% 52W High-60.24% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin- 52W Low17.18% ATR0.14
Employees58 Current Ratio2.60 Sales Q/Q-14.30% Oper. Margin- RSI (14)43.48 Volatility6.36% 3.45%
OptionableNo Debt/Eq1.82 EPS Q/Q52.70% Profit Margin- Rel Volume1.94 Prev Close2.82
ShortableYes LT Debt/Eq1.82 EarningsSep 28 BMO Payout- Avg Volume36.08K Price2.66
Recom2.00 SMA20-6.49% SMA50-2.93% SMA200-15.91% Volume70,039 Change-5.67%
Sep-25-18 08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga -5.67%
Sep-24-18 04:15PM  Novan Receives FDA Guidance for SB204 and Acne Indication GlobeNewswire
Aug-21-18 08:40AM  The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows Benzinga
Aug-20-18 11:44AM  Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication Benzinga
06:30AM  Novan Announces Promising Clinical Results with SB414 GlobeNewswire
Aug-08-18 12:45PM  New Novan incentive plan targets share price goals and $25M, $50M bonus pools American City Business Journals
08:25AM  Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract GlobeNewswire
Jul-16-18 07:06AM  Novartis had longer and more detailed relationship with Trump lawyer Michael Cohen, Senate report finds MarketWatch
Jun-13-18 08:05AM  Novan to Participate in Upcoming Investor Conferences GlobeNewswire
Jun-07-18 01:54PM  Does Novan Incs (NASDAQ:NOVN) Earnings Growth Make It An Outperformer? Simply Wall St.
Jun-01-18 08:05AM  Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-17-18 08:05AM  SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment GlobeNewswire
May-15-18 08:10AM  Novan Provides Update on SB414 Inflammatory Skin Disease Development Program GlobeNewswire
May-08-18 08:40PM  Trump attorney Cohen got about $500,000 from Russian oligarch, Stormy Daniels' lawyer claims CNBC
Apr-13-18 08:10AM  Same as the old boss Novan makes interim CEO permanent American City Business Journals
Apr-12-18 07:05AM  Novan Advances Organization and Strengthens Leadership Team GlobeNewswire
Apr-10-18 04:07PM  Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success? Simply Wall St.
Apr-09-18 07:20PM  Cramer: There's always a better time to sell CNBC Videos
06:31PM  Cramer: We got too negative on Fridaythere's always a be... CNBC Videos
Mar-29-18 08:05AM  Novan Announces Corporate Update Conference Call and Webcast GlobeNewswire
Mar-26-18 10:19PM  Novartis CEO on Alcon and Sandoz CNBC Videos -8.04%
Mar-25-18 04:54AM  Here's what CEOs and other leaders are saying at the China Development Forum in Beijing CNBC
Mar-07-18 01:16AM  Novartis expands alliance with Science 37 to advance virtual clinical trials program GlobeNewswire
Mar-06-18 01:17AM  Novartis' Xolair® recommended in new global chronic urticaria guideline GlobeNewswire
Mar-02-18 07:24AM  Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting GlobeNewswire
Mar-01-18 01:16AM  Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis GlobeNewswire
Feb-22-18 01:16AM  Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation GlobeNewswire
Feb-21-18 08:00AM  Dr. Eugene Sun Appointed to Novan Board of Directors GlobeNewswire
Feb-16-18 04:06PM  Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis GlobeNewswire
04:06PM  Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis GlobeNewswire
Feb-14-18 01:16AM  Novartis forms alliance to develop medicines for treating infectious diarrheal disease GlobeNewswire +5.86%
Feb-13-18 08:05AM  Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne GlobeNewswire +6.93%
01:17AM  Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis GlobeNewswire
Feb-08-18 01:16AM  Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis GlobeNewswire
Jan-31-18 05:01PM  Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL GlobeNewswire
Jan-30-18 03:45PM  SAS founder Goodnight's investment firm becomes Novan's largest stockholder American City Business Journals
Jan-25-18 02:10PM  2 Novan execs out as company pushes to broaden focus American City Business Journals
09:00AM  Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206 GlobeNewswire
Jan-24-18 04:02PM  Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss GlobeNewswire
02:48PM  Trading GE after earnings. Plus, the trade on Kroger & No... CNBC Videos
01:03PM  NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017 GlobeNewswire
01:02AM  Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase GlobeNewswire
Jan-22-18 04:36PM  Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments GlobeNewswire
Jan-18-18 05:31AM  Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars GlobeNewswire
Jan-17-18 01:16AM  Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL GlobeNewswire
Jan-16-18 01:16AM  Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients GlobeNewswire
01:02AM  Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA GlobeNewswire
Jan-11-18 09:15AM  Novan Announces Closing of Offering of Common Stock and Warrants GlobeNewswire
09:10AM  Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference GlobeNewswire
01:01AM  Novartis appoints Elizabeth Barrett as Oncology Head GlobeNewswire
Jan-09-18 01:16AM  Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** GlobeNewswire
Jan-05-18 12:40PM  Novan looks to raise $38M in public offering American City Business Journals -20.75%
09:00AM  Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants GlobeNewswire
Jan-04-18 04:07PM  Novan Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
01:16AM  Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) GlobeNewswire
Jan-03-18 01:16AM  Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer GlobeNewswire
Jan-02-18 10:46AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018 ACCESSWIRE
Jan-01-18 10:50PM  NOVAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN) Business Wire
Dec-29-17 10:50PM  NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN) Business Wire
01:45PM  The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN) ACCESSWIRE
Dec-28-17 02:43PM  NOVN INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Novan, Inc. Investors Business Wire
01:49PM  NOVN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018 ACCESSWIRE
10:45AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018 ACCESSWIRE
Dec-27-17 07:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN ACCESSWIRE
04:57PM  NOVAN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Novan, Inc. to Contact The Firm Business Wire
12:20PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN ACCESSWIRE
Dec-23-17 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline NOVN Business Wire
Dec-22-17 10:50PM  NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN) GlobeNewswire
04:44PM  Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label GlobeNewswire
01:16AM  Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma GlobeNewswire
Dec-21-17 10:43AM  The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN) ACCESSWIRE
Dec-20-17 09:47PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Novan, Inc. Investors and Encourages Investors to Contact the Firm (NOVN) Business Wire
04:10PM  Cohen Milstein Sellers & Toll PLLC Announces Investigation of Novan Inc. Business Wire
03:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN ACCESSWIRE
Dec-19-17 02:00AM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN ACCESSWIRE
Dec-18-17 02:36PM  NOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. Investors Business Wire
02:06PM  NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018 ACCESSWIRE
10:44AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018 ACCESSWIRE
09:33AM  Lawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders Foundation GlobeNewswire
Dec-15-17 10:50PM  NOVAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN) GlobeNewswire
02:00AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN ACCESSWIRE
Dec-14-17 12:30PM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2 Business Wire
02:00AM  The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN) GlobeNewswire
Dec-13-17 03:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN ACCESSWIRE
02:45PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN ACCESSWIRE
Dec-12-17 05:20PM  NOVAN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Novan, Inc. To Contact The Firm ACCESSWIRE
02:45AM  NOVN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018 GlobeNewswire
Dec-11-17 03:23PM  CORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class Action Business Wire -11.16%
03:00PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 NOVN GlobeNewswire
02:42PM  DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Novan, Inc. to Contact the Firm Business Wire
10:51AM  Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study GlobeNewswire
10:44AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline: January 2, 2018 ACCESSWIRE
Dec-10-17 10:40AM  Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer GlobeNewswire
Dec-09-17 08:00AM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline NOVN GlobeNewswire
Dec-08-17 10:50PM  NOVAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Novan, Inc. - (NOVN) Business Wire
01:16AM  Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine GlobeNewswire
Dec-07-17 03:00PM  The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN) ACCESSWIRE
Dec-06-17 06:57PM  Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class Action Business Wire
01:16PM  Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to... GlobeNewswire
11:11AM  UnitedHealth buys DaVita for $4.9B Yahoo Finance Video
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUNTER JEFF NEVP & Chief Business OfficerAug 22Option Exercise1.1211,66713,067186,666Aug 24 08:41 AM
PALMOUR JOHN WDirectorAug 22Buy2.6620,00053,200273,568Aug 24 08:43 AM
Martin G. KellyChief Executive OfficerAug 21Buy2.7130,00081,30030,000Aug 23 04:32 PM